title: Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab.
abstract: Immune checkpoint inhibitors are novel agents in the process of revolutionising cancer care. These agents have become a very appealing therapeutic alternative since they are much better tolerated than cytotoxic therapy, due to their relatively favorable toxicity profile. However, adverse events associated with these agents usually involve the immune system and can have serious implications jeopardising survival. Herein we report the first case of immune-mediated agranulocytosis due to Nivolumab therapy. The patient suffered from Staphylococcus infection during her agranulocytosis which only responded to high dose corticosteroid therapy.
authors: Hematology-Oncology Department, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada.
authors: Samer
authors: S
authors: Tabchi
authors: Hematology-Oncology Department, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada.
authors: Xiaoduan
authors: X
authors: Weng
authors: Hematology-Oncology Department, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada. Electronic address: normand.blais.chum@ssss.gouv.qc.ca.
authors: Normand
authors: N
authors: Blais
mesh_terms: D000368:Aged; D000380:Agranulocytosis / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology*; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D000074322:Antineoplastic Agents, Immunological / Q000009:adverse effects* / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology; D002289:Carcinoma, Non-Small-Cell Lung / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D004473:Ecthyma / Q000175:diagnosis / Q000209:etiology; D005260:Female; D006305:Health Status Indicators; D006801:Humans; D007958:Leukocyte Count; D008111:Liver Function Tests; D008175:Lung Neoplasms / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D000077594:Nivolumab
chemical_list: D000911:Antibodies, Monoclonal; D000074322:Antineoplastic Agents, Immunological; D000077594:Nivolumab
keywords: Agranulocytosis; Immune checkpoint inhibitors; Immune-mediated adverse events; Neutropenia; Nivolumab